Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Bortezomib

Review the clinical trials studying bortezomib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 30

Testing the Use of Combination Therapy in Adult Patients with Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Status: Active
Location: 595 locations
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Status: Active
Location: 512 locations
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
Status: Active
Location: 98 locations
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Status: Active
Location: 28 locations
Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) with the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
Status: Active
Location: 27 locations
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Status: Active
Location: 16 locations
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 14 locations
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Status: Active
Location: 14 locations
Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) plus Daratumumab in Newly Diagnosed Multiple Melanoma Patients with Cast Nephropathy or Monoclonal Gammopathy of Renal Significance (MGRS)
Status: Active
Location: 10 locations
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Status: Active
Location: 10 locations
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Status: Active
Location: 9 locations
Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Kidney Failure
Status: Active
Location: 8 locations
Minimal Residual Disease-Guided Treatment with or Without Autologous Hematopoietic Cell Transplantation and Teclistamab for Patients with Multiple Myeloma, The MASTER-2 Trial
Status: Active
Location: 7 locations
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma, ALTITUDE Trial
Status: Active
Location: 7 locations
Total Therapy for Infants with Acute Lymphoblastic Leukemia, The TINI 2 Study
Status: Active
Location: 6 locations
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 4 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Status: Active
Location: 7 locations
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Status: Active
Location: 5 locations
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma
Status: Active
Location: 3 locations
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Status: Active
Location: 3 locations
Adding Dasatinib or Venetoclax to Standard Chemotherapy for the Treatment in Children with T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoma or Mixed Phenotype Acute Leukemia, the SJALL23T Trial
Status: Active
Location: 3 locations
Standard Doses of Bortezomib and Pembrolizumab with or without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Study
Status: Active
Location: 2 locations
Bortezomib for the Treatment of Metastatic Castration-Resistant Prostate Cancer with PTEN Deletion, BORXPTEN Trial
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Minimal Residual Disease Response after Completing Therapeutic Drug Regimen with Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma, MILESTONE Trial
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Combination Chemotherapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas